Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
IPO Year: 2014
Exchange: NASDAQ
Website: adverum.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2024 | $25.00 | Outperform | Oppenheimer |
| 4/30/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/7/2022 | $4.00 | Hold → Buy | Truist |
| 7/23/2021 | Hold → Neutral | Cantor Fitzgerald | |
| 7/23/2021 | $23.00 → $3.00 | Overweight → Neutral | Cantor Fitzgerald |
| 7/23/2021 | $5.00 → $2.00 | Market Perform | SVB Leerink |
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $2.22 per share, equal to the per share closing price of Adverum's common st
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the first quarter of 2025. The company also provided pipeline highlights and a
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common
REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. "We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a potential best-in-class, one-and-done gene therapy. Ixo-vec offers the potential for life-long vision preservation and a favorable safety profile and is overwhelmingly preferred by patients over tod
REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $3.83 per share, Adverum's closing trading price on the grant date, and will vest over four years,
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ:AD
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMDNon-inferiority study to evaluate a single Ixo-vec injection compared to on-label aflibercept 2mg in both treatment-naïve and previously treated patients REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today announ
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,380 shares of common stock and restricted stock units (RSUs) for 22,790 shares of common stock to 5 new employees under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $4.20 per share, Adverum's closing
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage company that
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, at 4:40 p.m. ET. The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ:ADVM